Oligonucleotide Therapeutics Society (OTS) meeting in Denver

Advancing oligonucleotide therapeutics in Denver.

It was great to have Vadim Shchepachev, PhD representing Harness Therapeutics at the Oligonucleotide Therapeutics Society (OTS) meeting in Denver this week.

The event provided an opportunity to explore the latest advances in oligonucleotide therapeutics and their potential to address complex diseases, including neurodegenerative conditions.

An exciting time for the field as research continues to drive new therapeutic possibilities.

#OTS #OligonucleotideTherapeutics #RNAResearch #Neurodegeneration #HarnessTherapeutics

Our programmes

Huntington's Disease

Discover more

ALS and Alzheimer's

Discover more

Parkinson’s Disease

Discover more

Our news

June 2026

Harness Therapeutics Awarded Grant from The Michael J. Fox Foundation for Parkinson’s Research to Advance Parkinson's Disease Programme

February 2026

Harness Therapeutics Nominates HRN001, a First-in-Class Drug Candidate for Huntington’s Disease and Establishes Clinical Advisory Board

October 2025

Harness Therapeutics Announces Launch of MISBA® Duo Platform and Research Collaboration with Ono Venture Investment

June 2025

Harness Therapeutics Publishes HTT CAG Repeat Sizing Methodology Code on GitHub

View all